Title: 1 Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 RBD variants 2 with a novel competitive multiplex assay. 3

No abstract is available for this paper.

• Publication year

  2021

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

  2021cited by this paper
• Molecular dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417N and N501Y mutations (501Y.V2 variant) induces conformational change greater than N501Y mutant alone, potentially resulting in an escape mutant

  2021cited by this paper
• Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies

  2021cited by this paper
• Impact of South African 501.V2 Variant on SARS-CoV-2 Spike Infectivity and Neutralization: A Structure-based Computational Assessment

  2021cited by this paper
• Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization

  2021cited by this paper
• SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

  2020cited by this paper
• Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients

  2020cited by this paper
• Genomic characterization of a novel SARS-CoV-2

  2020cited by this paper
• Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays

  2020cited by this paper
• Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

  2020influential reference
• Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells

  2020cited by this paper
• Distinct systems serology features in children, elderly and COVID patients

  2020cited by this paper
• Immunogenic profile of SARS-CoV-2 spike in individuals recovered from COVID-19

  2020cited by this paper
• A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation

  2020cited by this paper
• Human neutralizing antibodies elicited by SARS-CoV-2 infection

  2020cited by this paper
• Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

  2020cited by this paper
• Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

  2020cited by this paper
• A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

  2020influential reference
• The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

  2020cited by this paper
• Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

  2020cited by this paper
• Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

  2020influential reference
• A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity

  2020cited by this paper
• Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding

  2020influential reference
• Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

  2020cited by this paper
• A simple protein-based surrogate neutralization assay for SARS-CoV-2

  2020cited by this paper
• Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology

  2020cited by this paper
• Spike Protein of SARS-CoV-2: Impact of Single Amino Acid Mutation and Effect of Drug Binding to the Variant-in Silico Analysis

  2020cited by this paper
• Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models

  2020cited by this paper
• The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity

  2020cited by this paper
• Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

  2020cited by this paper
• Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

  2020cited by this paper
• Genomic Characterization of a Novel SARS-CoV-2 Lineage from Rio de Janeiro, Brazil

  2020cited by this paper
• Convergent antibody responses to SARS-CoV-2 in convalescent individuals

  2020influential reference
• A Novel Coronavirus from Patients with Pneumonia in China, 2019

  2020cited by this paper
• A new coronavirus associated with human respiratory disease in China

  2020cited by this paper
• Transmission dynamics and evolutionary history of 2019‐nCoV

  2020cited by this paper
• Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

  2020cited by this paper
• Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

  2020cited by this paper
• Mapping the Evolutionary Potential of RNA Viruses.

  2018cited by this paper
• Data, disease and diplomacy: GISAID's innovative contribution to global health

  2017cited by this paper
• xMAP Technology: Applications in Detection of Pathogens

  2017cited by this paper
• Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus

  2017cited by this paper
• Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2

  2005cited by this paper
• Prior Infection and Passive Transfer of Neutralizing Antibody Prevent Replication of Severe Acute Respiratory Syndrome Coronavirus in the Respiratory Tract of Mice

  2004cited by this paper

• No citing papers are available for this paper.